Cargando…
Novel quantitative immunohistochemical analysis for evaluating PD-L1 expression with phosphor-integrated dots for predicting the efficacy of patients with cancer treated with immune checkpoint inhibitors
INTRODUCTION: Programmed cell death ligand 1 (PD-L1) expression in tumor tissues is measured as a predictor of the therapeutic efficacy of immune checkpoint inhibitors (ICIs) in many cancer types. PD-L1 expression is evaluated by immunohistochemical staining using 3,3´-diaminobenzidine (DAB) chronog...
Autores principales: | Ohkuma, Ryotaro, Miura, Sakiko, Muto, Satoshi, Toyomasu, Yoshitaka, Fujimoto, Yuki, Ieguchi, Katsuaki, Onishi, Nobuyuki, Shimizu, Takashi, Watanabe, Makoto, Takayanagi, Daisuke, Goshima, Tsubasa, Horiike, Atsushi, Hamada, Kazuyuki, Ariizumi, Hirotsugu, Shimokawa, Masahiro, Hirasawa, Yuya, Ishiguro, Tomoyuki, Suzuki, Risako, Iriguchi, Nana, Tsurui, Toshiaki, Mura, Emiko, Takenoshita, Sachiko, Numajiri, Kazuki, Okabe, Naoyuki, Yoshimura, Kiyoshi, Tsuji, Mayumi, Kiuchi, Yuji, Yajima, Toshiki, Ishida, Hideyuki, Suzuki, Hiroyuki, Yamochi, Toshiko, Kobayashi, Shinichi, Tsunoda, Takuya, Wada, Satoshi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10544572/ https://www.ncbi.nlm.nih.gov/pubmed/37790929 http://dx.doi.org/10.3389/fimmu.2023.1260492 |
Ejemplares similares
-
Monocyte subsets associated with the efficacy of anti‑PD‑1 antibody monotherapy
por: Ohkuma, Ryotaro, et al.
Publicado: (2023) -
Case Report: Combined pembrolizumab, 5-fluorouracil, and cisplatin therapy were remarkably effective in p16-positive squamous cell carcinoma of unknown primary
por: Suzuki, Risako, et al.
Publicado: (2023) -
Increased Plasma Soluble PD-1 Concentration Correlates with Disease Progression in Patients with Cancer Treated with Anti-PD-1 Antibodies
por: Ohkuma, Ryotaro, et al.
Publicado: (2021) -
Turicibacter and Acidaminococcus predict immune-related adverse events and efficacy of immune checkpoint inhibitor
por: Hamada, Kazuyuki, et al.
Publicado: (2023) -
A case of bronchial asthma as an immune-related adverse event of pembrolizumab treatment for bladder cancer: A case report
por: Hamada, Kazuyuki, et al.
Publicado: (2022)